Clinical trial · Interventional
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
NCT06249750CI-TRIAL-00073809recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Castration-resistant Prostate Cancer (CRPC) | Castration-Resistant Prostate Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperthermia | Device | — | UNRESOLVED |
| Immunotherapy | Drug | Immunotherapy | ALIAS |
| Targeted therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Immuno-targeted therapy group
- description
- ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d; RTK inhibitor regimen: Anlotinib, 12mg (at an initial dose of 12mg, later adjusted according to the instructions), po., d1\~14, q21d.
- interventionNames
- Drug: Immunotherapy
- Drug: Targeted therapy
- type
- EXPERIMENTAL
- label
- Hyperthermia-immuno-targeted therapy group
- description
- ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h. ICI regimen: Tislelizumab, 200mg, ivgtt., d2, q21d; RTK inhibitor regimen: Anlotinib, 12mg (at an initial dose of 12mg, later adjusted according to the instructions), po., d2\~15, q21d.
- interventionNames
- Drug: Immunotherapy
- Drug: Targeted therapy
- Device: Hyperthermia
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC; * Complete and reliable medical history and medical records; * No other primary tumors except CRPC; * Blood tests, liver function, renal function and electrocardiogram are basically normal; * Patients with ECOG score 0\~3, aged ≥18 years and \<90 years old; * Patients with good compliance, able to accept regular follow-up. Exclusion Criteria: * History of malignant tumor other than PC within the past 5 years; * Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study; * Accompanied by severe underlying diseases that cannot tolerate this therapy; * With acute diseases, such as acute infection, active bleeding; * Those who have recently participated in other clinical trials and have not passed the washout period; * Those who cannot tolerate systemic heat stress, such as claustrophobic patients; * Those who have a history of allergy to the drugs used in the trial; * Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.
References
Publications (0)
Data not yet available
No reference posted for this study.